# TSHA earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/TSHA) · [Earnings tab](https://www.lopjlb.com/stock/TSHA?tab=earnings) Updated: 2026-08-11T05:36:43 Quarters analyzed: 8 ## Cross-quarter narrative From mid‑2024 through early‑2026 TSHA’s earnings calls trace a shift from establishing trial safety and securing capital to solidifying regulatory pathways and scaling manufacturing. Early calls emphasized low‑dose safety, initiation of high‑dose cohorts, pediatric site expansion and a $76.8 M public raise to extend the cash runway. By late‑2024 the company reported FDA RMAT and CMC meetings, high‑dose enrollment and the first Part A dosing completion, while cash sufficiency remained a focus. In 2025 the narrative turned to regulatory alignment on the REVEAL pivotal design, IND amendment filings, a $230 M financing round extending runway to 2028, and the award of Breakthrough Therapy designation, accompanied by site activation and first patient dosing. Manufacturing readiness progressed through CMC lot approvals and a PPQ campaign. The most recent calls (2025‑Q4 to 2026‑Q1) highlight continued dosing in REVEAL and ASPIRE, ongoing BLA preparation, commercial infrastructure build‑out, and persistent questions around long‑term efficacy durability, enrollment speed, and reimbursement. Across the period safety signals remain favorable, but regulatory, enrollment, manufacturing and market‑access risks recur, albeit with improving alignment and funding stability. ## Latest CallCard · Q1 TSHA reports progress on TSHA-102 with FDA alignment, on‑track PPQ manufacturing, dosing in REVEAL and ASPIRE trials, and sufficient cash to 2028, while analysts probe procedure cost and screen‑fail rates. **Guidance:** maintained — No change to prior guidance; cash of $276.6M is expected to fund operations into 2028. **Tone:** mgmt 0.6 · Q&A pressure 0.4 · divergence 0.3 Management expressed confidence that CMC activities are on track, regulatory alignment is strong, and clinical milestones are progressing as planned. ### Demand visibility Strong demand for minimally invasive intrathecal delivery Clinicians and caregivers repeatedly expressed high interest in a lumbar puncture route, citing ease, scalability and outpatient feasibility. ### Margins / costs R&D spend up due to PPQ manufacturing initiatives R&D expenses rose to $33.8M from $15.6M, driven by BLA‑enabling PPQ campaign and higher clinical trial costs. ### Capital allocation Cash sufficient to fund operations into 2028 Cash and cash equivalents of $276.6M are expected to support planned operating expenses through 2028. ### Milestones - **TSHA-102 BLA submission** [on_track]: FDA alignment on pathway and interim analysis supports expedited submission. - **PPQ manufacturing campaign** [on_track]: Initiated in April; expected completion by Q4 2026. - **REVEAL pivotal trial dosing** [on_track]: Multiple patients dosed across sites; dosing expected to complete this quarter. - **ASPIRE trial dosing** [on_track]: Enrollment ongoing; dosing expected to finish this quarter. - **Part A long‑term data readout** [new]: Longer‑term follow‑up (≥12 months) from all 12 patients to be reported later this quarter. - **Commercial infrastructure build‑out** [on_track]: Senior commercial leadership hires completed; detailed plans to be shared H2 2026. - **Preclinical data presentation at ASGCT** [new]: New data on self‑complementary AAV9 vector to be presented May 14, 2026. - **Intrathecal route validation** [delivered]: Preclinical studies show comparable distribution to direct‑to‑brain delivery and strong clinician preference. ### Fears / risks - **Regulatory risk**: Potential delays in BLA approval or FDA feedback on interim analysis. - **Clinical efficacy durability**: Uncertainty about long‑term durability of functional gains beyond 12 months. - **Manufacturing scale‑up**: Risk that PPQ campaign may encounter issues affecting commercial supply. - **Screen‑failure uncertainty**: Limited public data on screen‑failure rates in Part B could affect enrollment projections. - **Reimbursement & pricing**: Cost differential between intrathecal and ICV procedures may impact payer acceptance. - **Competitive landscape**: Other gene‑therapy approaches for Rett syndrome could affect market share. - **Patient enrollment**: Enrollment across multiple sites must stay on schedule to meet dosing timelines. - **Safety profile**: Long‑term safety of intrathecal AAV9 delivery remains to be fully characterized. ### Key quotes > “We believe our consistent constructive dialogue with the FDA continues to support our streamlined path toward a potentially expedited BLA submission.” > “In Part A, as far as I recall, there were no screen failures. In Part B, we have not discussed the screen failures publicly at this point in time. But they are minimal.” ## Quarter one-liners - **2026 Q1:** TSHA reports progress on TSHA-102 with FDA alignment, on‑track PPQ manufacturing, dosing in REVEAL and ASPIRE trials, and sufficient cash to 2028, while analysts probe procedure cost and screen‑fail rates. - **2025 Q4:** TSHA reports FDA Breakthrough designation, alignment on pivotal and ASPIRE trials, and on‑track dosing for TSHA‑102, while highlighting strong market demand and ongoing commercial build‑out. - **2025 Q3:** TSHA reported FDA Breakthrough designation, on‑track first patient dosing and strong Phase I/II data for TSHA-102, while analysts probed statistical design and interim filing risk. - **2025 Q2:** TSHA reports FDA-aligned REVEAL pivotal trial site activation, $230M financing extending runway to 2028, and plans to start enrollment Q4 2025 while highlighting 100% response in Part A. - **2025 Q1:** Taysha reports strong regulatory and clinical progress for TSHA-102, expects to submit an IND amendment this quarter and start pivotal trial enrollment by Q4 2025, with cash lasting into Q4 2026. - **2024 Q4:** TSHA reports completed Part A dosing of TSHA-102 with encouraging safety, aims for pivotal trial design update in H1 2025, and cash runway to Q4 2026. - **2024 Q3:** TSHA reports solid regulatory progress and encouraging early safety data for TSHA‑102, while analysts probe high‑dose safety and pediatric translatability. - **2024 Q2:** TSHA reported encouraging low‑dose safety/efficacy data, began high‑dose dosing, expanded pediatric sites and raised $76.8 M to fund TSHA‑102 through Q4 2026. ## Theme arcs - **Regulatory alignment and approvals** (improving): Progress from early RMAT meetings to Breakthrough designation, FDA alignment on pivotal design, and BLA submission. - **Clinical safety profile** (improving): Consistently reported encouraging safety for low and high doses with no serious adverse events. - **Funding and cash runway** (improving): Initial $76.8 M raise followed by $230 M financing extending runway to 2028. - **Trial enrollment and site activation** (improving): Expansion to five sites, REVEAL site activation, and enrollment of plateau cohort patients. - **Manufacturing scale‑up** (improving): CMC lot approvals, PPQ campaign, and commercial‑scale manufacturing alignment. - **Market demand and commercial build‑out** (stable): Strong clinician and caregiver interest; ongoing commercial infrastructure development. - **Biomarker measurement gap** (new): First noted lack of MECP2 CSF/blood assay limiting pharmacodynamic confirmation. - **Efficacy durability uncertainty** (stable): Repeated concerns about long‑term functional gains beyond 12 months. ## Guidance path 2024 Q2:maintained → 2024 Q3:maintained → 2024 Q4:maintained → 2025 Q1:maintained → 2025 Q2:maintained → 2025 Q3:maintained → 2025 Q4:maintained → 2026 Q1:maintained --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/TSHA`